Discover more insights into Abiraterone Acetate アビラテロンアセテート

Abiraterone Acetate sentence examples within metastatic castration resistant



Cortisol as biomarker for CYP17 inhibition in mCRPC patients treated with abiraterone acetate.


Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans.

Abiraterone Acetate sentence examples within androgen deprivation therapy



Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.


Metastatic hormone-sensitive prostate cancer: How should it be treated?

Abiraterone Acetate sentence examples within advanced prostate cancer



Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells


Study protocol for a comparative effectiveness evaluation of abiraterone acetate against enzalutamide: a longitudinal study based on Swedish administrative registers



Abiraterone Acetate sentence examples within castration resistant prostate



Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors


Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis.

Abiraterone Acetate sentence examples within prostate specific antigen



Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer


Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.

Abiraterone Acetate sentence examples within castration‐resistant prostate cancer



Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer


Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration‐resistant prostate cancer

Abiraterone Acetate sentence examples within metastatic prostate cancer



Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer


Angiotensin System Inhibitors May Improve Outcomes of Patients With Castration-Resistant Prostate Cancer During Abiraterone Acetate Treatment—A Cardio-Oncology Study

Abiraterone Acetate sentence examples within resistant prostate cancer



Radium 223 combined with new hormone therapies for the treatment of castrate-resistant metastatic prostate cancer: scientific evidence and sharing of our experience.


PD15-11 SURVIVAL RATES AND ECONOMIC OUTCOMES IN CHEMOTHERAPY-NAïVE METASTATIC CASTRATE RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE ACETATE OR ENZALUTAMIDE

Abiraterone Acetate sentence examples within progression free survival



Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation


Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

Abiraterone Acetate sentence examples within metastatic castration‐resistant prostate



Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment


Combined 177Lu‐PSMA‐617 PRLT and abiraterone acetate versus 177Lu‐PSMA‐617 PRLT monotherapy in metastatic castration‐resistant prostate cancer: An observational study comparing the response and durability

Abiraterone Acetate sentence examples within metastatic castration sensitive



Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.


Abiraterone Acetate for Metastatic Castration-Sensitive Prostate Cancer

Abiraterone Acetate sentence examples within metastatic hormone sensitive



Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer


The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer

Abiraterone Acetate sentence examples within radiographic progression free



A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)

Abiraterone Acetate sentence examples within castration sensitive prostate



Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model.

Abiraterone Acetate sentence examples within high risk metastatic



Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer

Abiraterone Acetate sentence examples within Inhibitor Abiraterone Acetate



Androgen receptor signalling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration sensitive prostate cancer.


Androgen synthesis inhibition but not gonadectomy reduces persistence during strategy set-shifting and reversal learning in male rats

Abiraterone Acetate sentence examples within Plu Abiraterone Acetate



Triple-arm androgen blockade for advanced prostate cancer: a review


Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.

Abiraterone Acetate sentence examples within Starting Abiraterone Acetate



Circulating and intra-tumoral adrenal androgens correlate with response to abiraterone in men with castration resistant prostate cancer.


Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer

Abiraterone Acetate sentence examples within Background Abiraterone Acetate



Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study


Angiotensin System Inhibitors May Improve Outcomes of Patients With Castration-Resistant Prostate Cancer During Abiraterone Acetate Treatment—A Cardio-Oncology Study

Abiraterone Acetate sentence examples within Drug Abiraterone Acetate



New stability indicating RP-HPLC method for the determination of Abiraterone acetate, its related substances and degradation products in bulk and dosage form


Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Abiraterone Acetate sentence examples within Include Abiraterone Acetate



Warning against second‐generation antiandrogen for metastatic castration sensitive prostate cancer


A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics

Abiraterone Acetate sentence examples within Initiating Abiraterone Acetate



Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer


A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens

Abiraterone Acetate sentence examples within Either Abiraterone Acetate



The Real-World Experience of Single-Center, Retrospective Study of the Prognostic Effect of Secondary Hormone Agent on Survival in Patients With Hormone-Refractory Metastatic Prostate Cancer


Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong’s perspective

Abiraterone Acetate sentence examples within Receiving Abiraterone Acetate



Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy


Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration‐resistant prostate cancer receiving abiraterone acetate: An evidence‐based case report and review of literature

Abiraterone Acetate sentence examples within abiraterone acetate plu



Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry


A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate‐resistant prostate cancer


Herb–drug interactions between androgenic Chinese herbal medicines and androgen receptor antagonist on tumor growth: Studies on two xenograft prostate cancer animal models



Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan



The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design



Medullary Aplasia Revealing a Metastatic Prostatic Adenocarcinoma



Clinical outcomes in 21-hydroxylase deficiency



Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor



KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer.



Metastatic prostate cancer: clinical aspects and treatment limitations in a university hospital center in Senegal



Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.



Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer



Pharmacokinetics of abiraterone acetate released from a tablet based on lipid matrix in beagle dogs.



An up-to-date evaluation of abiraterone for the treatment of prostate cancer



Deepening of response to prostate-specific membrane antigen ligand-targeted radioligand therapy beyond end of treatment



Comparative efficacy of docetaxel versus novel hormonal agent in de novo metastatic hormone-sensitive prostate cancer: Real-world data curated by deidentified chart abstraction.



The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions



Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer



A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss



Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with Abiraterone or Enzalutamide.



Antiandrogen abiraterone and docetaxel treatments affect Notch1, Jagged1 and Hes1 expressions in metastatic prostate cancer cells.



AQbD Driven Development of a RP-HPLC Method for the Quantitation of Abiraterone acetate for Its Pharmaceutical Formulations in presence of Degradants



Tumor Induced Osteomalacia in Patients With Metastatic Prostate Cancer: Case Report and Literature Review



A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer



Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art



Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer.



Development and Validation of a Sensitive GC-MS/MS Method for the Determination of Five Potential Genotoxic Impurities in Abiraterone Acetate.



QbD-Based Development and Validation of an Efficient RPHPLC Method for Estimation of Abiraterone Acetate in Bulk, Tablet, and In-House-Developed Nano-Formulation



Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer



Validity of cycloheximide chylomicron flow blocking method for the evaluation of lymphatic transport of drugs.



The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer.



The current state of prostate cancer in Antigua & Barbuda—2021



Abiraterone acetate/rosuvastatin interaction



Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial.



Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy Prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.



Abiraterone acetate



Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From “All-Comers” to “Personalized” Approach



Adrenocortical carcinoma xenograft in zebrafish embryos as model to study the in vivo cytotoxicity of abiraterone acetate.



Considering bone health in the treatment of prostate cancer bone metastasis based on the results of the ERA-223 trial



Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers



Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer



Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer



Docetaxel for hormone-naïve prostate cancer (PCa): Results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial



Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone.



Safety of Abiraterone Acetate Administration in Elderly Patients Receiving Peritoneal Dialysis with Castration-Resistant Prostate Cancer: Two Case Reports.



Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: Results from the Dutch CAPRI-registry



Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN



Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer



Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.



Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.



Evolution of androgen receptor variant (ARV) profiles in serial metastatic solid and liquid biopsies in metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate/ prednisone (AA/P).



Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): Results from the Dutch CAPRI registry


Learn more from Abiraterone Acetate アビラテロンアセテート

Abiraterone Acetate アビラテロンアセテートの概要


Abiraterone Acetate アビラテロンアセテート
Encyclopedia 百科事典